IPSC

Century Therapeutics Inc

Wall Street Zen downgraded shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Century Therapeutics in a research note issued on...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been given an average recommendation of "Hold" by the seven ratings firms that are presently covering the stock, Marketbeat.com reports...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,289,543 shares, an increase of 19.3% from the March 15th total of 8,626,834 shares. Based on an average daily volume...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 8,626,834...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 10,076 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The stock was...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) SVP Douglas Carr sold 7,043 shares of the company's stock in a transaction on Thursday, March 12th. The stock was sold at an average price...

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...